6.
Alonso-Miguel D, Valdivia G, Garcia-San Jose P, Alonso-Diez A, Clares I, Portero M
. Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate. Vet Comp Oncol. 2021; 20(1):179-188.
DOI: 10.1111/vco.12760.
View
7.
Canadas A, Franca M, Pereira C, Vilaca R, Vilhena H, Tinoco F
. Canine Mammary Tumors: Comparison of Classification and Grading Methods in a Survival Study. Vet Pathol. 2018; 56(2):208-219.
DOI: 10.1177/0300985818806968.
View
8.
Goldschmidt M, Pena L, Rasotto R, Zappulli V
. Classification and grading of canine mammary tumors. Vet Pathol. 2011; 48(1):117-31.
DOI: 10.1177/0300985810393258.
View
9.
Wouda R, Hocker S, Higginbotham M
. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study. Vet Comp Oncol. 2017; 16(1):E52-E60.
DOI: 10.1111/vco.12332.
View
10.
de Araujo M, Campos L, Ferreira E, Cassali G
. Quantitation of the Regional Lymph Node Metastatic Burden and Prognosis in Malignant Mammary Tumors of Dogs. J Vet Intern Med. 2015; 29(5):1360-7.
PMC: 4858035.
DOI: 10.1111/jvim.13576.
View
11.
Machado M, Costa-Neto J, Portela R, DAssis M, Martins-Filho O, Barrouin-Melo S
. The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma. PLoS One. 2018; 13(10):e0204830.
PMC: 6171873.
DOI: 10.1371/journal.pone.0204830.
View
12.
LeBlanc A, Atherton M, Bentley R, Boudreau C, Burton J, Curran K
. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021; 19(2):311-352.
PMC: 8248125.
DOI: 10.1111/vco.12677.
View
13.
Vieira T, Oliveira E, Jaime Dos Santos B, Souza F, Veloso E, Nunes C
. COX-2 expression in mammary invasive micropapillary carcinoma is associated with prognostic factors and acts as a potential therapeutic target in comparative oncology. Front Vet Sci. 2022; 9:983110.
PMC: 9510711.
DOI: 10.3389/fvets.2022.983110.
View
14.
Simon D, Schoenrock D, Baumgartner W, Nolte I
. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med. 2006; 20(5):1184-90.
DOI: 10.1892/0891-6640(2006)20[1184:patimm]2.0.co;2.
View
15.
Chon E, McCartan L, Kubicek L, Vail D
. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. Vet Comp Oncol. 2012; 10(3):184-93.
DOI: 10.1111/j.1476-5829.2011.00265.x.
View
16.
Queiroga F, Pires I, Lobo L, Lopes C
. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours. Res Vet Sci. 2009; 88(3):441-5.
DOI: 10.1016/j.rvsc.2009.10.009.
View
17.
de M Souza C, Toledo-Piza E, Amorin R, Barboza A, Tobias K
. Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J. 2009; 50(5):506-10.
PMC: 2671873.
View
18.
Abadie J, Nguyen F, Loussouarn D, Pena L, Gama A, Rieder N
. Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. Breast Cancer Res Treat. 2017; 167(2):459-468.
PMC: 5790838.
DOI: 10.1007/s10549-017-4542-8.
View
19.
Pena L, De Andres P, Clemente M, Cuesta P, Perez-Alenza M
. Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: relationship with clinical and histological characteristics. Vet Pathol. 2012; 50(1):94-105.
DOI: 10.1177/0300985812447830.
View
20.
Karayannopoulou M, Kaldrymidou E, Constantinidis T, Dessiris A
. Adjuvant post-operative chemotherapy in bitches with mammary cancer. J Vet Med A Physiol Pathol Clin Med. 2001; 48(2):85-96.
DOI: 10.1046/j.1439-0442.2001.00336.x.
View